First, I'm pleased to report that we acquired the majority interest in Aurion Biotech. Aurion is at the ... approved in Japan under the trade name Vyznova. In the U.S., we plan to launch Phase ...

The CEO and several other leaders were pushed out after another company acquired a majority stake last month. Forterra sells Tukwila motel property to Islamic center This new nonprofit aims to ...

Biotechnology offers a scalable alternative, but realizing its full potential requires commitment from governments and space agencies. By harnessing biological processes such as microbial and ...

In September 2024, Aurion announced the first global commercial launch of this technology, Vyznova™ (which includes neltependocel ... Learn more at www.alcon.com. About Aurion Biotech, Inc. Aurion ...

Aurion launched Vyznova in Japan for bullous keratopathy, marking a significant milestone in its commercial strategy. Alcon announced it has acquired a majority interest in Aurion Biotech, a ...

In September 2024, Aurion announced the first global commercial launch of this technology, Vyznova™ (which includes ... About Aurion Biotech, Inc. Aurion Biotech’s mission is to restore ...

In September 2024, Aurion launched Vyznova™, its first commercial cell therapy product in Japan, for the treatment of bullous keratopathy, a condition that seriously threatens vision.

today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases. Aurion will operate as a separate ...

GENEVA, March 26, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority ...

SEATTLE & CAMBRIDGE, Mass & TOKYO, March 18, 2025--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing ...